![Kenji Harada](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Kenji Harada
Nessuna posizione attualmente
Provenienza dei contatti di primo grado di Kenji Harada
Entità | Tipo di entità | Settore Industriale | |
---|---|---|---|
Public Company | Pharmaceuticals: Major | 10 | |
Extinct | Pharmaceuticals: Major | 5 |
Grafico delle società connesse in secondo grado
Relazione in diverse aziende
Società connesse a Kenji Harada tramite i suoi contatti personali
Società | Settore | Persone collegate | Posizione principale |
---|---|---|---|
Agouron Pharmaceuticals LLC
![]() Agouron Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Agouron Pharmaceuticals LLC develops and distributes therapeutic products. It provides therapeutic products which are used in the treatment of cardiovascular disease, central nervous system diseases and disorders, neurological disorders, inflammatory diseases, respiratory diseases, infectious diseases, immunological disorders, pharmaceutical preparations and other diseases. The company was founded in 1984 and is headquartered in San Diego, CA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
PFIZER, INC. | Pharmaceuticals: Major | Sales & Marketing Corporate Officer/Principal Corporate Officer/Principal | |
Millennium Pharmaceuticals, Inc.
![]() Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal | |
CANADIAN IMPERIAL BANK OF COMMERCE | Regional Banks | Corporate Officer/Principal | |
HSBC HOLDINGS PLC | Major Banks | Chief Executive Officer | |
Anadys Pharmaceuticals, Inc.
![]() Anadys Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Anadys Pharmaceuticals, Inc. develops and manufactures novel small molecule medicines. It engages in developing novel medicines in the areas of hepatitis C and oncology. The firm develops ANA598, a direct-acting antiviral for the treatment of hepatitis C. The company was founded by Stelios B. Papadopoulos and Kleanthis G. Xanthopoulos in 1992 and is headquartered in Little Falls, NJ. | Pharmaceuticals: Major | Chief Executive Officer Corporate Officer/Principal | |
HSBC Securities (USA), Inc.
![]() HSBC Securities (USA), Inc. Regional BanksFinance Founded in 1969, HSBC Securities (U.S.A.) Inc. is an SEC-registered brokerage firm and registered futures commission merchant located in New York City. The firm is a wholly-owned subsidiary of HSBC North America Holdings, Inc. and their ultimate parent is HSBC Holdings Plc. (NYSE: HBC). HSBC Securities (U.S.A.) is a member of FINRA, the NYSE and the SIPC. Their securities and annuity products are provided by registered representatives and insurance agents of HSBC Securities (U.S.A.). In California, HSBC Securities (U.S.A.) conducts insurance business as HSBC Securities Insurance Services. Insurance products are offered through insurance agents of HSBC Insurance Agency (U.S.A.) Inc., a wholly-owned subsidiary of HSBC Bank U.S.A. NA and an indirectly wholly-owned subsidiary of HSBC Holdings plc. The company also engages in investment banking underwriting, dealing and brokering of debt and equity securities and futures contracts and is a primary dealer in U.S. Government and federal agency securities. | Regional Banks | Corporate Officer/Principal | |
Renetx Bio, Inc.
![]() Renetx Bio, Inc. BiotechnologyHealth Technology Renetx Bio, Inc. operates as a biotechnology company that develops disease modifying therapeutics. It offers Nogo Receptor and Cellular Prion Protein technology. The company was founded by Sylvia McBrinn and Stephen Strittmatter in 2009 and is headquartered in New Haven, CT. | Biotechnology | Director of Finance/CFO | |
MPM BioImpact, Inc
![]() MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Private Equity Investor | |
Nextech Invest AG
![]() Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals. | Investment Managers | Chief Executive Officer Chief Investment Officer | |
University of Cambridge | College/University | Doctorate Degree | |
University of Michigan | College/University | Undergraduate Degree Undergraduate Degree | |
DOTTIKON ES HOLDING AG | Chemicals: Specialty | Director/Board Member | |
The University of Sydney | College/University | Undergraduate Degree | |
University of Basel | College/University | Doctorate Degree Doctorate Degree | |
INTELLIA THERAPEUTICS, INC. | Biotechnology | Chief Tech/Sci/R&D Officer | |
Orna Therapeutics, Inc.
![]() Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes. | Biotechnology | Director/Board Member | |
The Genetics Co., Inc.
![]() The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Medical/Nursing Services | Chairman | |
Kyoto University | College/University | Graduate Degree | |
CARGO THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Nextech Holding AG | Chairman | ||
Nextech III GP AG | Director/Board Member | ||
Dottikon Exclusive Synthesis AG
![]() Dottikon Exclusive Synthesis AG Pharmaceuticals: MajorHealth Technology Dottikon Exclusive Synthesis AG manufactures pharmaceutical ingredients. Its products and services exclusive synthesis, project management, performance chemicals, containment, quality management, recycling and waste treatment, and dottisol. The company was founded in 1913 and is headquartered in Dottikon, Switzerland. | Pharmaceuticals: Major | Director/Board Member | |
Dottikon Es Management AG | Director/Board Member | ||
Dedman College of Humanities & Sciences | College/University | Director/Board Member | |
HSBC Holdings Plc /US Auto Finance Business/ | Finance/Rental/Leasing | Corporate Officer/Principal | |
The EQUUS Foundation, Inc.
![]() The EQUUS Foundation, Inc. Agricultural Commodities/MillingProcess Industries The EQUUS Foundation, Inc. operates an animal welfare organization that cares for horses. The non-profit company is based in Westport, CT. | Agricultural Commodities/Milling | Corporate Secretary | |
VOYAGER THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO | |
TURNSTONE BIOLOGICS CORP. | Biotechnology | Director of Finance/CFO | |
IVERIC BIO, INC. | Pharmaceuticals: Generic | Director/Board Member | |
AKERO THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
Axerion Pharmaceuticals, Inc. | Director of Finance/CFO | ||
INVIVYD, INC. | Biotechnology | Director of Finance/CFO | |
Ventus Therapeutics, Inc.
![]() Ventus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ventus Therapeutics, Inc. operates as a biopharmaceutical company. It focuses in developing novel small molecule medicines that target the innate immune system to treat autoimmune diseases, inflammatory diseases and cancer. The company was founded by Hao Wu, Richard Flavell, Judy Lieberman, Thomas Tuschl, and Feng Shao and is headquartered in Montreal, Canada. | Pharmaceuticals: Major | Director/Board Member | |
Ventus Therapeutics U.S., Inc.
![]() Ventus Therapeutics U.S., Inc. Medical DistributorsDistribution Services Ventus Therapeutics U.S., Inc. operates as a biotechnology company. The company is headquartered in Natick, MA. | Medical Distributors | Director/Board Member | |
Swiss Scientific Computing Center
![]() Swiss Scientific Computing Center Miscellaneous Commercial ServicesCommercial Services The Swiss Scientific Computing Center develops and provides supercomputing capabilities to solve important problems in science and society. The private company is based in Manno, Switzerland. | Miscellaneous Commercial Services | Chief Executive Officer | |
APOGEE THERAPEUTICS, INC. | Biotechnology | Director of Finance/CFO | |
Cleave Therapeutics, Inc.
![]() Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
Swiss Federal Institute of Technology | College/University | Chief Administrative Officer |
Statistiche
Distribuzione geografica
Stati Uniti | 32 |
Svizzera | 12 |
Canada | 3 |
Regno Unito | 3 |
Giappone | 3 |
Settori
Health Technology | 23 |
Finance | 10 |
Consumer Services | 8 |
Commercial Services | 4 |
Process Industries | 3 |
Posizioni
Director/Board Member | 84 |
Corporate Officer/Principal | 52 |
Independent Dir/Board Member | 27 |
Chairman | 21 |
Director of Finance/CFO | 20 |
Contatti più connessi
Insiders | |
---|---|
Daniel Lynch | 32 |
Jane Henderson | 25 |
Chen Schor | 23 |
Alfred Scheidegger | 20 |
William LaRue | 15 |
Hironori Hozoji | 13 |
Karen L. Tubridy | 13 |
Stephen Worland | 12 |
Martin Mattingly | 10 |
Myoung-Ok Kwon | 10 |
Paul Walker | 9 |
Thomas Barnes | 8 |
Casey Logan | 8 |
Patricia Bitar | 8 |
Jennifer Ellis | 5 |
- Borsa valori
- Insiders
- Kenji Harada
- Connessioni Società